Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peramivir - BioCryst Pharmaceuticals

Next Previous
Drug Profile

Peramivir - BioCryst Pharmaceuticals

Alternative Names: ALPIVAB; BCX-1812; JNJ-2; PeramiFlu; Peramivir injection - BioCryst Pharmaceuticals; Rapiacta; Rapivab; RWJ-270201

Latest Information Update: 04 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Alabama
  • Developer BioCryst Pharmaceuticals; GC Biopharma; Seqirus; Shionogi
  • Class Acetamides; Antivirals; Carboxylic acids; Cyclopentanes; Guanidines; Small molecules
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype; Influenza virus infections

Most Recent Events

  • 04 Jan 2024 No development reported - Phase-III for Influenza virus infections (In adolescents, In children, In infants) in South Africa (IV)
  • 04 Dec 2023 m8 Pharmaceuticals has been acquired by Acino
  • 30 Nov 2022 9375182- No update

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top